Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | MAOB | P27338 | 7/20 | 0.55 |
| ▸ | MAOA | P21397 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | XDH | P47989 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.47 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL2105293 | 0.95 | CA12 (0.54) | CA12CA9MAOBMAOAPOLB | |
| SCHEMBL6597993 | 0.86 | TSHR (0.48) | CA12CA9NPC1MAPTRAB9A | |
| SCHEMBL31415605 | 0.81 | CA12 (0.65) | CA12CA9MAOBMAOAPOLB | |
| SCHEMBL28399285 | 0.80 | MAOB (0.56) | CA12CA9MAOBMAOAPOLB | |
| SCHEMBL8618928 | 0.79 | CA12 (0.55) | CA12CA9MAOBMAOAPOLB | |
| SCHEMBL8382142 | 0.79 | CA12 (0.55) | CA12CA9MAOBMAOAPOLB | |
| SCHEMBL18936062 | 0.79 | MAOB (0.55) | CA12CA9MAOBMAOAPOLB | |
| SCHEMBL5177829 | 0.79 | CA12 (0.57) | CA12CA9MAOBMAOAPOLB | |
| SCHEMBL17199261 | 0.79 | MAOB (0.55) | CA12CA9MAOBMAOAPOLB | |
| SCHEMBL12778676 | 0.79 | MAOB (0.55) | CA12CA9MAOBMAOAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355705-A1 | DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS | THE UNIVERSITY OF HONG KONG (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230355705-A1 | DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS | THE UNIVERSITY OF HONG KONG (CN) | 2023-11-09 | — | — | US | disclosed |
| US-9376430-B2 | Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-06-28 | — | — | US | disclosed |
| US-9333193-B2 | Compositions and methods for treating tuberculosis | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-05-10 | — | — | US | disclosed |
| US-8835644-B2 | Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-8629126-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC. (JP) | 2014-01-14 | — | — | US | disclosed |
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-05-31 | — | — | US | disclosed |
| US-8133882-B2 | Quinolone derivative or pharmaceutically acceptable salt thereof | ASTELLAS PHARMA INC (JP) | 2012-03-13 | — | — | US | disclosed |
| US-5055473-A | QUINOLINYL SULFONAMIDE ANTI-ARRHYTHMIC AGENTS AND USE THEREAS | PFIZER INC. (US) | 1991-10-08 | — | — | US | disclosed |
| EP-0285323-B1 | ANTIARRHYTHMIC AGENTS | Pfizer Limited (GB) | 1990-11-28 | — | — | EP | disclosed |
| US-4956382-A | TERTIARY AMINE HETEROCYCLIC SULFONAMIDES | PFIZER INC. (US) | 1990-09-11 | — | — | US | disclosed |
| EP-0286277-B1 | ANTIARRYTHMIC AGENTS | Pfizer Limited (GB) | 1990-06-20 | — | — | EP | disclosed |
| EP-0281254-B1 | ANTIARRYTHMIC AGENTS | Pfizer Limited (GB) | 1990-01-17 | — | — | EP | disclosed |
| US-4829071-A | Quinolyl substituted indane sulfonamides and their use as anti-arrhythmic agents | PFIZER INC. (US) | 1989-05-09 | — | — | US | disclosed |
| US-4822793-A | Benzazepine antiarrhythmic agents | PFIZER INC. (US) | 1989-04-18 | — | — | US | disclosed |
| EP-0286277-A1 | Antiarrythmic agents | Pfizer Limited (GB) | 1988-10-12 | — | — | EP | disclosed |
| EP-0285323-A1 | Antiarrhythmic agents | Pfizer Limited (GB) | 1988-10-05 | — | — | EP | disclosed |
| EP-0281254-A1 | Antiarrythmic agents | Pfizer Limited (GB) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120136025-A1 | QUINOLONE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | P2RY10, P2RY12, P2RY11 | CA12 3007/4885CA9 3168/4885MAOB 2719/4885 |
| US-20230355705-A1 | DISCOVERY OF YEATS2 YEATS DOMAIN INHIBITORS AS NOVEL ANTI-CANCER AGENTS | YEATS2, YEATS4, KNTC1 | CA12 4217/4885CA9 3963/4885MAOB 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.